MSA Advisors LLC Has $5.75 Million Stock Position in Eli Lilly and Company $LLY

MSA Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 149.9% in the first quarter, HoldingsChannel reports. The firm owned 6,248 shares of the company’s stock after buying an additional 3,748 shares during the period. Eli Lilly and Company makes up 1.7% of MSA Advisors LLC’s portfolio, making the stock its 11th largest position. MSA Advisors LLC’s holdings in Eli Lilly and Company were worth $5,747,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Tanager Wealth Management LLP boosted its stake in shares of Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after acquiring an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC raised its stake in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after acquiring an additional 10 shares during the period. Wealthspan Partners LLC lifted its holdings in Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after purchasing an additional 10 shares during the last quarter. G&S Capital LLC boosted its position in Eli Lilly and Company by 2.0% during the fourth quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after purchasing an additional 10 shares during the period. Finally, Serenus Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Serenus Wealth Advisors LLC now owns 439 shares of the company’s stock valued at $472,000 after purchasing an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,222.61 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The firm has a 50-day moving average price of $1,144.84 and a two-hundred day moving average price of $1,041.89. The company has a market capitalization of $1.15 trillion, a P/E ratio of 43.43, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts anticipate that Eli Lilly and Company will post 35.03 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Sanford C. Bernstein upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Truist Financial upped their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Berenberg Bank boosted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and investors remain optimistic about Lilly’s earnings momentum. The company generated $19.8 billion in first-quarter revenue, up roughly 55.5% year over year, and recent analyst price targets have generally exceeded the current trading level. The median target from 14 analysts is $1,336, with targets as high as $1,500. Eli Lilly Stock Opinions on Growth and AI Ventures
• Positive Sentiment: Lilly’s expanding oncology and newer-medicine portfolio is expected to contribute meaningfully to second-quarter results, supplementing demand for its GLP-1 franchise. This diversification could reduce reliance on weight-loss and diabetes products while supporting long-term revenue growth. Here’s How LLY’s Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
• Positive Sentiment: The company is making a reported $2.8 billion investment aimed at expanding growth beyond GLP-1 drugs. Investors also highlighted Lilly’s investments in artificial-intelligence drug discovery, data infrastructure and potential opportunities in emerging treatment categories. Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
• Neutral Sentiment: Institutional trading was mixed: 2,169 investors added shares in the latest quarter, while 1,653 reduced positions. Several large holders made sizable sales, offset by substantial purchases from other institutions. Social-media commentary also emphasized Lilly’s revenue scale and sustained earnings power, but these discussions are not formal company guidance. Eli Lilly Stock Opinions on Growth and AI Ventures
• Negative Sentiment: Insider activity included one reported open-market sale by an executive involving 2,500 shares. While the transaction is relatively small compared with Lilly’s market value, it provides a modest counterpoint to the otherwise bullish coverage. Eli Lilly Stock Opinions on Growth and AI Ventures

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.